(Press-News.org) A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and destroys cancer cells—can recruit immune cells to penetrate and persist deep within brain tumors. The research, which is published in Cell, provides details on how this therapy prolonged survival in patients with glioblastoma, the most common and malignant primary brain tumor, in a recent clinical trial.
“Patients with glioblastoma have not benefited from immunotherapies that have transformed patient care in other cancer types such as melanoma because glioblastoma is a 'cold' tumor with poor infiltration by cancer-fighting immune cells,” said co-senior author Kai Wucherpfennig, MD, PhD, chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute. “Findings from our clinical trial and our mechanistic study show that is now feasible to bring these critical immune cells into glioblastoma.”
The oncolytic virus used in the team’s trial, which was developed by E. Antonio Chiocca, MD, PhD, Executive Director of the Center for Tumors of the Nervous System at Mass General Brigham Cancer Institute, is made from a herpes simplex virus genetically altered so it can only make copies of itself in glioblastoma cells and not normal healthy cells. The virus spreads to a glioblastoma cell, kills it, and then makes a copy of itself that spreads again to another glioblastoma cell. Infection of cells with the virus also triggers an immune response. In the phase 1 trial of 41 patients with recurrent glioblastoma, the oncolytic virus treatment extended survival compared to historically reported survival, especially among those with pre-existing viral antibodies.
In their Cell study, the investigators examined the extent of this immune response in clinical trial participants. Their analysis revealed that the treatment induced long-term infiltration of immune T cells into patients’ tumors. Closer proximity of cytotoxic T cells with dying brain tumor cells was associated with longer patient survival after treatment. The therapy also expanded pre-existing T cells in the brain.
“We show that increased infiltration of T cells that are attacking tumor cells translates into a therapeutic benefit for patients with glioblastoma,” said Chiocca, who is also a co-senior author of the study. “Our findings could have important implications for a cancer whose standard of care hasn’t changed for 20 years.”
Authorship: In addition to Wucherpfennig and Chiocca, authors include Maxime Meylan, Ye Tian, Lijian Wu, Alexander L. Ling, Daniel Kovarsky, Graham L. Barlow, Linh D. Nguyen, Jason Pyrdol, Sascha Marx, Lucas Westphal, Julius Michel, L. Nicolas Gonzalez Castro, Sydney Dumont, Andres Santos, Itay Tirosh, and Mario L. Suva.
Paper cited: Meylan M et al. “Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial” Cell DOI: 10.1016/j.cell.2025.12.055
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.
Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.
As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,200 clinical trials.
END
Coral reefs are undoubtedly in crisis. Scientists have documented concerning coral bleaching events, dramatic declines in coral cover, fish and shark populations across the Caribbean over recent decades. But a critical question has remained unanswered: has the way energy flows through reef ecosystems also changed? A new study led by scientists at the Smithsonian Tropical Research Institute (STRI) and published in Nature reveals that it has, profoundly. Food chains on modern Caribbean reefs are 60-70% shorter than they were 7,000 years ago, and individual fish have lost the dietary specialisation that ...
The American College of Lifestyle Medicine (ACLM) has announced the availability of its updated dietary position statement meant to guide clinicians in the treatment, reversal and prevention of chronic disease. The statement is the result of a year of work by a multi-member expert task force led by Associate Professor and Chair, Department of Nutrition, Rosalind Franklin University of Medicine and Science Melissa Bernstein, PhD, RDN, LD, FAND, DipACLM, FACLM, and ACLM Senior Director of Research Micaela Karlsen, PhD, MSPH. This update coincides with a key time of increased national attention on nutrition.
As the Institute for Health Metrics ...
CHICAGO, Feb. 11, 2026 – As Americans focus on heart health during American Heart Month, a newly published scientific review highlights pecans – America’s native nut – and their role in heart-healthy diets. Published in the peer-reviewed journal Nutrients, the comprehensive analysis synthesizes more than 20 years of research on pecans and reinforces positive evidence related to cardiovascular health and overall diet quality, while also identifying promising areas for future research.
Conducted by researchers at the Illinois Institute ...
“In this article, we assess the risk of developing haematopoietic cancers post-modRNA vaccination based on current scientific literature and explore the reported potential genetic and molecular mechanisms involved in disease pathogenesis.”
BUFFALO, NY – February 11, 2026 – A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled “Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms.”
In this report, led by first author Patrizia Gentilini along with corresponding ...
WASHINGTON (Feb. 11, 2026) — The quality of a low-carbohydrate or low-fat diet may matter more than the amount of carbohydrates or fat consumed when it comes to reducing heart disease risk, according to a new study published in JACC, the flagship journal of the American College of Cardiology. Researchers found that versions of both diet patterns emphasizing macronutrients from healthy foods were associated with a lower risk of coronary heart disease (CHD), while versions high in refined carbohydrates and animal products were linked to higher risk and adverse ...
Key points:
Low-carbohydrate and low-fat diets rich in high-quality, plant-based foods and low in animal products and refined carbohydrates were linked with lower risk of heart disease, while the same diets that were rich in refined carbohydrates and high in animal products and other low-quality foods were associated with a higher risk of heart disease. The study suggests that it’s the quality of the macronutrients composing these diets that make a difference for heart health, rather than the quantity.
According to the researchers, the findings help debunk the myth that simply modulating carbohydrate or fat intake is inherently beneficial.
Boston, ...
(WASHINGTON, Feb. 11, 2026) — The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population. Both guidelines, grounded in evidence-based practice, were developed by pediatric and adult experts in collaboration with patient representatives to improve outcomes for this vulnerable patient population. They were published in the Society’s peer-reviewed journal Blood Advances.
“Caring for these individuals is complex ...
LOS ANGELES — City of Hope® Research Spotlight offers a glimpse into groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, life-threatening diseases. Each spotlight features research-related news, such as recognitions, collaborations and the latest research defining the future of medical treatment.
To learn more about research at City of Hope, one of the largest and most advanced cancer research and treatment organizations ...
As Norway and other nations begin to scale up the storage of CO2 in undersea geologic reservoirs, research from the Norwegian University of Science and Technology (NTNU) is helping answer two important questions about this storage.
“Where has my CO2 gone? Is it leaking or not?” says Martin Landrø, an NTNU geophysicist and director of the university’s Centre for Geophysical Forecasting (CGF). “Those are the basic questions actually.”
This is like a revolution in visualization and understanding of what's happening.
Norway ...
Chemotherapy remains one of the most powerful tools in the fight against cancer, yet it often comes with significant long-term side effects that can dramatically affect patients’ quality of life. Among the most debilitating is Chemotherapy-Induced Peripheral Neuropathy, which impacts both the central and peripheral nervous systems and affects up to 85% of cancer patients and survivors.
Docetaxel is a chemotherapy drug that kills cancer cells by disrupting microtubules, structures essential for cell division. However, microtubules are also critical for nerve function, so docetaxel can damage nerve endings, axons and mitochondria, causing neuropathic symptoms such as ...
